Cellceutix Provides Update on Uplist Application

BEVERLY, MA--(Marketwired - June 08, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today provided shareholders an update on the status of the Company's application to uplist to the NASDAQ exchange. Cellceutix last week learned that the application remains pending due to the price of CTIX stock currently below the minimum requirement.

Cellceutix wishes to reiterate its stance that it will not perform a reverse split to meet the higher share price requirement. The Company is of the opinion that a number of near-term pipeline developments will remedy any concern with an uplist on the merits of the continued strong fundamentals of Cellceutix.

Expected developments in the coming weeks and months include the conclusion of the Phase 1 trial of Kevetrin for solid tumors and initiation of mid-stage trials of Kevetrin for solid and liquid tumors; the ongoing Phase 2 trial of Brilacidin-OM for oral mucositis; and the start of the Phase 2 trial of Prurisol for psoriasis. Additionally, Cellceutix is meeting with the U.S. Food and Drug Administration in the upcoming weeks to discuss initiating a Phase 3 trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections.

"As a large shareholder myself, my intentions are squarely aligned with all CTIX shareholders and I will do what is best to grow corporate value," commented Leo Ehrlich, Chief Executive Officer at Cellceutix. "We believe our drug compounds are as valuable as any top drug candidates in development today."

Sign-up for Cellceutix email alerts is available at http://cellceutix.com/email-alerts/#sthash.VNkn7FY9.dpbs.

About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antimicrobial applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix has begun a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of Oral Mucositis in patients with head and neck cancer. Brilacidin-OM, a defensin mimetic compound, has shown in an animal model to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.

Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause Cellceutix's actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. Cellceutix has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are Cellceutix's need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock to Aspire Capital; the fact that Cellceutix's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.